Summary
Guardant Health, Inc. (GH) announced a significant financing event through the issuance of $1.15 billion in 0% Convertible Senior Notes due 2027, with an additional $150 million issued under an option, bringing the total to $1.3 billion. These notes are senior, unsecured obligations that do not bear regular interest but may accrue special or additional interest under specific default scenarios. The conversion price is set at approximately $139.82 per share, with a potential for an increased conversion rate in the event of a "Make-Whole Fundamental Change." The company also entered into capped call transactions to mitigate potential dilution from these notes, with a cap price of approximately $182.60 per share.
Key Highlights
- 1Issuance of $1.15 billion aggregate principal amount of 0% Convertible Senior Notes due 2027.
- 2Full exercise of the option to purchase an additional $150 million in Notes, bringing the total issuance to $1.3 billion.
- 3The Notes mature on November 15, 2027, and do not bear regular interest, but can accrue special/additional interest under default conditions.
- 4Initial conversion rate of 7.1523 shares per $1,000 principal amount, implying an initial conversion price of approximately $139.82 per share.
- 5Company entered into Capped Call Transactions to mitigate potential dilution from note conversions, with a cap price of approximately $182.60 per share.
- 6The Notes are senior, unsecured obligations, subordinated to secured debt and structurally subordinated to subsidiary debt.
- 7The issuance was made to "qualified institutional buyers" under Rule 144A, with shares issuable upon conversion relying on Section 3(a)(9) of the Securities Act.
Frequently Asked Questions
This filing reports on the entry into a material definitive agreement, specifically the issuance of $1.15 billion (and an additional $150 million) of 0% Convertible Senior Notes due 2027 and related capped call transactions. This indicates a significant financing event for Guardant Health.
The conversion of these notes can lead to the issuance of new shares, potentially diluting existing shareholders. However, Guardant Health has entered into Capped Call Transactions designed to offset this dilution, up to a cap price of approximately $182.60 per share.
The notes are 0% convertible senior notes due 2027, meaning they don't pay regular interest. They are convertible into Guardant Health's common stock at an initial price of approximately $139.82 per share. The company can redeem the notes after November 20, 2024, under certain conditions, and noteholders can require repurchase upon a "Fundamental Change" event.
The notes are unsecured and subordinated to secured debt. If certain "Events of Default" occur, the principal amount could become due and payable. There are also specific provisions for "Fundamental Changes" and "Make-Whole Fundamental Changes" that could affect the notes' terms or trigger repurchase/conversion rights.